| 1型糖尿病的免疫治疗 |
| |
| 引用本文： | 何斌斌,周智广. 1型糖尿病的免疫治疗[J]. 中国实用内科杂志, 2020, 40(1): 25-29. DOI: 10.19538/j.nk2020010105 |
| |
| 作者姓名： | 何斌斌 周智广 |
| |
| 作者单位： | 中南大学湘雅二医院代谢内分泌科糖尿病免疫学教育重点实验室国家代谢性疾病临床医学研究中心，湖南长沙410011 |
| |
| 基金项目： | 国家自然科学基金青年科学基金（81600649） |
| |
| 摘 要： | 1型糖尿病（T1DM）是一种自身免疫性疾病，人们希望基于发病机制进行免疫干预治疗可以达到预防和逆转T1DM的目的。近30余年，免疫干预临床试验逐渐开展，包括免疫调节药物、调节性T细胞、干细胞治疗和胰岛移植等。尽管这些试验通过抑制自身免疫应答或胰岛B细胞替代，可以延缓胰岛B细胞功能的衰退或短期内脱离胰岛素治疗，但仍有各自的局限性。文章将结合最新的临床试验数据对免疫干预治疗T1DM的研究进展进行总结和展望。
|
| 关 键 词： | 1型糖尿病 免疫调节药物 细胞治疗 |
Immunotherapy for type 1 diabetes mellitus |
| |
| HE Bin-bin,ZHOU Zhi-guang. Immunotherapy for type 1 diabetes mellitus[J]. Chinese Journal of Practical Internal Medicine, 2020, 40(1): 25-29. DOI: 10.19538/j.nk2020010105 |
| |
| Authors: | HE Bin-bin ZHOU Zhi-guang |
| |
| Affiliation: | (Department of Metabolism and Endocrinology,the Second Xiangya Hospital,Central South University,Changsha 410011,China) |
| |
| Abstract: | Type 1 diabetes mellitus(T1DM)is an autoimmune disease. It is hoped that immune intervention based on pathogenesis can prevent and reverse T1DM. In the past 30 years,clinical trials of immune intervention have been conducted gradually,including immunoregulatory drugs,regulatory T cells,stem cell therapy and islet transplantation. Although these trials can delay the decline of islet function or be free from insulin-dependent therapy in a short term by inhibiting the autoimmune response or islet β cell replacement,they also have limitations. This article summarized the progress of immune intervention for T1DM based on the latest clinical trial data,and put forward prospects. |
| |
| Keywords: | type 1 diabetes immunoregulatory drugs cell therapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国实用内科杂志》浏览原始摘要信息 |
|
点击此处可从《中国实用内科杂志》下载全文 |
